vibegron (Gemtesa) Report issue

Small molecule Approved FDA
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21
  • InChIKey: DJXRIQMCROIRCZ-XOEOCAAJSA-N
  • Mol. Mass: 444.54
  • ALogP: 2.77
  • ChEMBL Molecule:
    vibegron  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

krp-114v | mk-4618 | n-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide | vibegron

Organizations (10)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (3)


 

Urinary Bladder, Overactive (approved 2020)

Urinary Incontinence

Urinary Incontinence, Urge

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Hypertension (Phase 1)

Irritable Bowel Syndrome (Phase 2)

Urinary Bladder (Phase 2/Phase 3)

Urinary Bladder, Overactive (Phase 4)

Urinary Incontinence (Phase 4)

Urinary Incontinence, Urge ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue